#USA #Philadelphia #Settlement #Generic Drugs #Prescription

Legal Notice for Settlement Claims on Prescription Drugs

In a pivotal development, Fine, Kaplan and Black, R.P.C. has announced that individuals who incurred costs for certain prescription generic drugs in the United States between May 1, 2009, and December 31, 2019, may be eligible to file claims as part of a collective settlement totaling $533 million. This notification, authorized by a federal court, is designed to inform those affected about their rights and potential compensation.

Who Qualifies?

To qualify for this settlement, you must have been a part of the End-Payer class, which includes both consumers and third-party payers like insurance companies or employers with self-funded prescription drug plans. If you directly purchased or reimbursed for one or more specified generic drugs for personal use during the specified timeframe (excluding Indiana and Ohio), you may fall under this class.

What is the Nature of the Lawsuit?

This lawsuit arises from allegations that various generic drug manufacturers violated federal and state antitrust laws, leading to inflated costs for consumers and third-party payers. The defendants in this case include companies such as Sandoz Inc., Apotex Corp., and Sun Pharmaceutical Industries, among others. These companies have denied any wrongdoing, and the legal proceedings continue against those who have not settled.

Settlement Details

The settlement involves substantial financial contributions from the involved parties. Sandoz has agreed to pay $275 million, while Sun/Taro has settled for $200 million. An additional $10 million and $48 million will come from Heritage Pharmaceuticals and Apotex, respectively. It's important to note that the remaining settlement amounts, minus administrative costs and legal fees, will be distributed to qualifying claimants.

How to File a Claim

To take advantage of this settlement, it is critical to file a claim by submitting the required form and supporting documents. Claims must be submitted electronically via the EPP Settlement Website by November 9, 2026, or postmarked by that date if sent by mail. Here, claimants can access claims forms and additional detailed information on the qualification and submission processes.

Once your claim is validated, you will receive a payment proportionate to the amount you paid for the qualified drugs during the claim period. The total amount you may receive will depend on the number of valid claims submitted and the expenditures calculated for the specified generic drugs.

Important Dates and Information

All claims must be submitted no later than November 9, 2026. If you miss this deadline, you will forfeit your right to any compensation from the settlement. A helpline (1-877-316-0171) is available for those seeking further guidance or questions regarding the claim process.

For more details, please navigate to GenericDrugsEndPayerSettlement.com for a comprehensive guide on class definitions, included drugs, and further clarification about the settlement.

Conclusion

This substantial settlement serves to address the alleged wrongdoings within the pharmaceutical industry concerning generic drug pricing. If you believe you qualify, don’t hesitate to act soon and submit your claims to potentially receive compensation as part of this landmark lawsuit.